Skip to main content

Advertisement

Table 1 Patient characteristics (n = 526).

From: Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer – a retrospective analysis: JMTO LC03-02

Characteristic No. patients % patients Mean (± SD)
Age (years) 526   66.2
(range 27–91)
Sex    
   Male 336 64  
   Female 190 36  
Histological type    
   Adenocarcinoma 360 69  
   Squamous cell carcinoma 123 23  
   Other 43 8  
History of smoking    
   No 170 32  
   Yes 319 61  
   Unknown 37 7  
ECOG performance status    
   0–1 321 61  
   2–4 191 36  
   Unknown 14 3  
Concurrent interstitial pneumonitis    
   No 500 95  
   Yes 26 5  
Concurrent pulmonary emphysema    
   No 447 85  
   Yes 77 15  
   Unknown 2 <1  
History of pulmonary tuberculosis    
   No 491 93  
   Yes 34 7  
   Unknown 1 <1  
Prior surgery for lung cancer    
   No 337 64  
   Yes 189 36  
Prior chemotherapy for lung cancer    
   No 115 22  
   Yes 411 78  
Prior thoracic radiotherapy for primary lung cancer    
   No 330 63  
   Yes 194 37  
   Unknown 2 <1  
Concurrent chemotherapy with agent other than gefitinib    
   No 485 92  
   Yes 41 8  
Thoracic radiotherapy concurrent with or after gefitinib treatment    
   No 478 91  
   Yes 48 9  
Absolute neutrophil count (/μL) 485   4786 (± 3331)
Eosinophil count (/μL) 483   163 (± 181)
Creatinine level (mg/dL) 496   0.77 (± 0.44)
Platelet count (×104/μL) 515   25.8 (± 10.3)
Albumin level (g/dL) 424   3.67 (± 0.58)
Aspartate aminotransferase level (IU/L) 487   25 (± 20)
Alanine aminotransferase level (IU/L) 515   23 (± 25)
Lactate dehydrogenase level (IU/L) 495   279 (± 318)